Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus (Nasdaq: SLP) announced extensions of two research collaborations with the U.S. Food and Drug Administration and the National Institute of Environmental Health Sciences. The projects advance AI-enabled computational toxicity models and new approach methodologies (NAMs) for food, chemical, and environmental safety assessment. The FDA extension expands access to curated toxicological datasets for further training, validation, and benchmarking of Simulations Plus’ AI/ML models. The NIEHS extension continues application of the company’s software to design, validate, and benchmark experimental systems under national chemical safety modernization efforts.
Simulations Plus (Nasdaq: SLP) announced CEO Shawn O’Connor will participate in multiple investor conferences in February–March 2026, including BTIG (Feb 10, Snowbird, UT), TD Cowen (Mar 3, Boston, MA) and KeyBanc (Mar 18, virtual).
Formats include one-on-one meetings and fireside chats; webcast links will be available on the company Investor Relations site.
Simulations Plus (Nasdaq: SLP) hosted a 2026 Virtual Investor Day on January 21, 2026, outlining its strategy to evolve from best-in-class tools into an integrated, AI-enabled modeling ecosystem for drug development.
The company emphasized alignment with FDA and EMA principles for good AI practice, combining mechanistic modeling, AI-assisted workflows, cloud execution, and regulator-ready reproducibility to address rising scientific complexity and demand for in silico evidence.
Executive leaders highlighted priorities: validated science, transparency, traceability, and enterprise infrastructure to support customers and regulators.
Simulations Plus (Nasdaq: SLP) reported Q1 FY2026 results for the quarter ended Nov 30, 2025: total revenue $18.4M (down 3% YoY), software revenue $8.9M (down 17%), services revenue $9.5M (up 16%). Gross profit was $10.9M with gross margin 59% (versus 54% prior year). GAAP net income was $0.7M (diluted EPS $0.03); adjusted net income was $2.6M (adjusted diluted EPS $0.13). Adjusted EBITDA was $3.5M (19% of revenue). The company reaffirmed FY2026 guidance: revenue $79M–$82M, software mix 57–62%, adjusted diluted EPS $1.03–$1.10, and adjusted EBITDA margin 26–30%. A virtual Investor Day is scheduled for Jan 21, 2026.
Simulations Plus (Nasdaq: SLP) will host a virtual Investor Day on January 21, 2026 to outline its long-term strategy for model-informed drug development (MIDD).
The 90-minute webcast (1:00 PM–2:30 PM ET) will cover the company’s unified product and technology strategy, advances in scientific services across the drug lifecycle, the industry environment and accelerating adoption of MIDD, and the company’s financial priorities and outlook, followed by a leadership Q&A. A replay will be posted after the event.
Simulations Plus (NASDAQ: SLP) will report first quarter fiscal 2026 results after market close on Thursday, January 8, 2026. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
Investors can join via live webcast (registration required), dial 1-877-451-6152 (U.S.) or 201-389-0879 (international), or request a return call via Call me™. A replay will be available on the company investor relations page approximately one hour after the call.
Simulations Plus (Nasdaq: SLP) on December 9, 2025 positioned its validated modeling engines and AI-orchestrated ecosystem to respond to the FDA's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The company highlights integration of PBPK (GastroPlus), QST/QSP (BIOLOGXsym), and population modeling (MonolixSuite) to support weight-of-evidence assessments and reduced animal testing.
Simulations Plus plans continued biologics modeling enhancements and frames its tools as aligned with FDA emphasis on mechanistic, model-informed nonclinical decision-making.
Simulations Plus (NASDAQ: SLP) reported fiscal 2025 results and reaffirmed fiscal 2026 guidance. FY2025 total revenue was $79.2M (+13% vs prior year) with software revenue $45.8M (58% mix) and services $33.4M (42% mix). Adjusted EBITDA was $22.0M (28% margin) and adjusted diluted EPS was $1.03. The company recorded a $77.2M non-cash impairment, producing a GAAP net loss of $64.7M and diluted loss per share of $3.22 for FY2025. Q4 revenue was $17.5M (-6% YoY) with software down 9% to $9.0M. Management reaffirmed FY2026 guidance of $79–$82M revenue and adjusted diluted EPS $1.03–$1.10 and announced a Virtual Investor Day on Jan 21, 2026 to present its AI product vision.
Simulations Plus (Nasdaq: SLP) provided preliminary fiscal 2025 results and issued fiscal 2026 guidance on October 22, 2025. Key preliminary fiscal 2025 metrics include $79.1M revenue, 13% revenue growth, 58% software mix, 28% adjusted EBITDA margin, and $1.03 adjusted diluted EPS. For fiscal 2026 management issued preliminary guidance of $79M–$82M revenue, 0–4% revenue growth, 57–62% software mix, 26–30% adjusted EBITDA margin, and $1.03–$1.10 adjusted diluted EPS. Results are preliminary and unaudited; final audited results and a full fiscal 2025 report will be filed on Form 10-K and released on December 1, 2025.
Management cited challenging market conditions and outlined a multi‑year Cloud and AI product vision, noting the launch of GastroPlus X.2 on S+ Cloud and planned expansion of AI capabilities.
Simulations Plus (NASDAQ:SLP), a leading provider of cheminformatics and biosimulation solutions for the biopharma industry, has announced its participation in two major investor conferences in September 2025.
CEO Shawn O'Connor will attend the 2025 Wells Fargo Healthcare Conference in Boston on September 3-4, featuring a fireside chat on September 3 at 12:45 PM ET. Additionally, he will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City on September 10, with a fireside chat scheduled for 2:35 PM ET.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
